UK Markets closed

Onxeo SA (ONXEO.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
2.4300-0.0500 (-2.02%)
At close: 04:44PM CEST
Full screen
Previous close2.4800
Open2.5050
Bid2.4250 x 0
Ask2.5450 x 0
Day's range2.4050 - 2.5050
52-week range2.2500 - 4.8750
Volume4,392
Avg. volume9,309
Market cap226.716M
Beta (5Y monthly)1.46
PE ratio (TTM)N/A
EPS (TTM)-0.9120
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Onxeo: Initial IND Application for AsiDNA Granted "Study May Proceed" by the U.S. FDA

    PARIS, June 30, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced that the U.S. Food and Drug Administration (FDA) has cleared the initial IND for its first-in-class drug candidate AsiDNA. This is the first US IND Onxeo filed since the US team came on board in

  • Business Wire

    Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022

    PARIS, June 16, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), ("Onxeo" or the "Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, announces that the Combined General Meeting held today adopted all resolutions presented, in accordance with the Board of Directors’ recommendations.

  • Business Wire

    Onxeo: Publication of the 2021 Annual Financial Report

    PARIS, April 28, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced the publication of the Company’s 2020 annual financial report.